Delivering powerful cancer testing solutions through our novel NextAmp™ Analysis System – a customizable and dual functionality system, capable of performing both multi-gene expression (PanelChip®) and digital qPCR applications (DigiChip™)
2023 BIO ASIA-Taiwan
A Chip-based Clinically Oriented qPCR
NextAmp™ Analysis System
Virtual Exhibition
JUL 27 - JUL 30
Oncogenic Druggable Fusion
First line screening for possible fusion-targeted therapy
Indeterminate
Thyroid Nodule Cytology
Solution: Risk stratification through fast, affordable molecular analysis
Insight to Action
Transform your research into clinical-actionable product
NextAmp™
Analysis System
A dual-functioning system capable of multi-biomarker analysis and digital detection of low quantity genes
Innovation through Collaborations
We collaborate for your success by customizing smarter and more suitable biomarker solution to meet your clinical needs
High Tolerance for Sample Quality
Our assays enable more patients to receive suitable drug treatments with the ability to analyze poor quality and low concentration samples
Pinpoint Eligible Patients
PanelChip® offers a cost-effective platform for large scale screening of patient with rare gene rearrangements
Proven Clinical Utility with Expression Biomarkers
Translating discoveries into products, we have helped multiple companies develop mRNA- and miRNA-based assay
Unparalleled Biopharma Solutions
As an enabling technology, NextAmp™ Analysis System offers multiple advantages over Next Generation Sequencing, making it ideal for the development of companion diagnostics during clinical trials and post-marketing commercialization.
Learn more
Collaborator’s Testimonial
“We routinely work with difficult samples such as FFPE, which often cannot meet the quality requirements needed to be run on available genetic testing platforms today. In contrast, NextAmp™ Analysis System provides the flexibility to design amplicons for fragmented RNA, making it possible to develop assays that deal with FFPE samples of various quality.”
Dr. Hua Chien Chen, CEO
ACT Genomics Co.
“QuarkBio’s PanelChip™ multiplexing capability allows us to detect more than 25 respiratory pathogen in one qPCR experiment. The advantage has helped us achieve throughput that we’ve never imagined would be possible!”
